You are here:

MS in the media - 17 November 2017

Published on

11 - 17 November 2017

These are links to news stories from the last week that may be of interest to people in the UK. The link beneath each item will take you to the original story.

Please note that the MS Trust did not write the original items and does not endorse their content nor any claims made in them.

To keep up to date on all the latest news, views and research on multiple sclerosis, sign up for Open Door, our free newsletter or regular email alerts

Ocrevus licensed for relapsing and progressive MS

Ocrevus (Ocrelizumab) has received a licence as a new disease modifying drug for both relapsing remitting MS and early primary progressive MS.

Source: PharmaTimes

MS Trust link: Ocrevus (Ocrelizumab)

 

Gilenya effective for children with MS

The first trial of a disease modifying drug in people under the age of 18 found that Gilenya (fingolimod) reduced the relapse rate by 82%. The headline suggests the drug improved vision and bladder symptoms, though this was not part of the trial. The results were presented at ECTRIMS

Source: Daily Mail

MS Trust link: Childhood MS

Social care failing people with disabilities

The MS Society has published a new report on social care and how people with MS are not getting the support they need.

Source: Guardian

MS Trust link: Social care

Wii a useful way to exercise

A small study in Dorset found that regular exercise with a Nintendo Wii helped improve walking and balance as well as physical and psychological well-being

Source: MS News Today

MS Trust link: Could computer games help with MS symptoms?